NuvaRing Lawsuit Filed by Alonso Krangle on Behalf of a Louisiana Woman Who Developed Pulmonary Embolism Allegedly Due to NuvaRing Use
A NuvaRing lawsuit recently filed by Alonso Krangle alleges that the plaintiff’s use of NuvaRing caused her to develop a serious lung condition known as pulmonary embolism and that Organon and others failed to warn the public about the risk of such serious side effects associated with NuvaRing use.
New York, NY (PRWEB) July 28, 2013
Alonso Krangle’s attorneys have recently filed a NuvaRing lawsuit against Organon, Merck and others on behalf of a woman from Louisiana. This case (Case No. 2:13-cv-03678-SDW-MCA) was filed June 13, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be Organon USA, Inc., N.V. Organon, the Schering Corporation, Merck & Co., Inc., and Merck Sharp & Dohme.
In addition to alleging that use of NuvaRing caused the plaintiff to develop a serious lung condition known as pulmonary embolism, this case alleges that Organon and the other defendants knew but failed to publicly disclose the fact that NuvaRing had a higher risk of blood clot-related complications than oral contraceptives. Furthermore, this NuvaRing lawsuit contends that Organon and the other defendants failed to adequately safety test NuvaRing and negligently marketed NuvaRing as a safe and effective birth control medication without warning consumers about the potential risks of serious NuvaRing side effects.
Alonso Krangle’s experienced NuvaRing lawsuit attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
According to court documents in this NuvaRing lawsuit, the plaintiff began using NuvaRing in December 2006. After developing chest pain, coughing and shortness of breath, in July 2012, she sought medical attention and underwent a CT scan, at which time she was informed that she had developed multiple pulmonary emboli. Pulmonary emboli are blood clots lodged in the lungs that can severely impair breathing and result in life-threatening complications. Following this diagnosis, the plaintiff was hospitalized for two days, was advised to stop using NuvaRing and was placed under anticoagulation therapy, including Lovenox and Coumadin. While the plaintiff had to continue her anticoagulation therapy after being released from the hospital, she has also had to undergo regular follow-up care to monitor her health.
Risk of Serious Complications Associated with NuvaRing Use
The link between NuvaRing use and the development of serious blood clot disorders like pulmonary embolism has been reported by many medical researchers within recent years. In fact, in 2012, a study published in the New England Journal of Medicine reported that vaginal rings like NuvaRing could nearly triple women’s risk of developing blood clots, when compared to the risk associated with older birth control pills.
( nejm.org/doi/full/10.1056/NEJMoa1111840 )
Another study published in May 2012 in the British Medical Journal found that women’s risk of developing blood clots increased at least 6.5 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
( bmj.com/content/344/bmj.e2990#alternate )
Seeming to support the alleged link between NuvaRing use and serious blood clots is information from the FDA’s Adverse Events Reporting System (AERS), which has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). Among the most commonly reported adverse effects patients reported after NuvaRing use were more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, upwards of 30 percent of women who reported NuvaRing complications required hospitalization, and approximately 3 percent of NuvaRing complications resulted in death.
( adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING )
About Alonso Krangle LLP And Filing A NuvaRing Lawsuit
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have dedicated their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is offering FREE NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact 1-800-403-6191 or visit the website, FightForVictims.com. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10963121.htm